(Q37073084)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18237851%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

review article

1 reference

title

Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18237851%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

0 references

1 February 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18237851%20AND%20SRC:MED&resulttype=core&format=json

Lancet Oncology Commission

2 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18237851%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18237851%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18237851%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

page(s)

168-175

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18237851%20AND%20SRC:MED&resulttype=core&format=json

Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death

2 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970029-9

7 January 2021

Docetaxel in combination with doxorubicin or vinorelbine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970029-9

7 January 2021

Taxol: mechanisms of action and resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970029-9

7 January 2021

Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970029-9

7 January 2021

The role of ABC transporters in drug resistance, metabolism and toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970029-9

7 January 2021

Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970029-9

7 January 2021

Chemoresistance in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970029-9

7 January 2021

Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified beta-tubulin isotypes.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970029-9

7 January 2021

Expression of class III beta-tubulin reduces microtubule assembly and confers resistance to paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970029-9

7 January 2021

Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970029-9

7 January 2021

Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970029-9

7 January 2021

Mechanisms of taxotere-related drug resistance in pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970029-9

7 January 2021

Structure and utilization of tubulin isotypes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970029-9

7 January 2021

Class III β‐tubulin in human development and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970029-9

7 January 2021

Class III beta-tubulin isotype: a key cytoskeletal protein at the crossroads of developmental neurobiology and tumor neuropathology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970029-9

7 January 2021

Mechanisms of Taxol resistance related to microtubules.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970029-9

7 January 2021

Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970029-9

7 January 2021

Vinorelbine (Navelbine): a third-generation vinca alkaloid

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970029-9

7 January 2021

High-resolution model of the microtubule

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970029-9

7 January 2021

Location and properties of the taxol binding center in microtubules: a picosecond laser study with fluorescent taxoids

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970029-9

7 January 2021

Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970029-9

7 January 2021

Removal of beta III isotype enhances taxol induced microtubule assembly

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970029-9

7 January 2021

Antisense oligonucleotides to class III beta-tubulin sensitize drug-resistant cells to Taxol

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970029-9

7 January 2021

BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970029-9

7 January 2021

Multidisciplinary management of lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970029-9

7 January 2021

American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970029-9

7 January 2021

Isolated extrarenal papillary carcinoma in a child

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970029-9

7 January 2021

Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970029-9

7 January 2021

Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non–Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970029-9

7 January 2021

Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970029-9

7 January 2021

Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970029-9

7 January 2021

Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970029-9

7 January 2021

Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970029-9

7 January 2021

Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970029-9

7 January 2021

Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970029-9

7 January 2021

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970029-9

7 January 2021

Class III -Tubulin Expression and Benefit from Adjuvant Cisplatin/Vinorelbine Chemotherapy in Operable Non-Small Cell Lung Cancer: Analysis of NCIC JBR.10

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970029-9

7 January 2021

Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970029-9

7 January 2021

Expression of beta-tubulin isotypes in human primary ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970029-9

7 January 2021

Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970029-9

7 January 2021

Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970029-9

7 January 2021

Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970029-9

7 January 2021

Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970029-9

7 January 2021

Cloning and characterization of the 5'-flanking region of the rat neuron-specific Class III beta-tubulin gene

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970029-9

7 January 2021

The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970029-9

7 January 2021

The betaI/betaIII-tubulin isoforms and their complexes with antimitotic agents. Docking and molecular dynamics studies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970029-9

7 January 2021

Targeting the microtubules in breast cancer beyond taxanes: the epothilones

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970029-9

7 January 2021

Assessing the clinical impact of prognostic factors: when is "statistically significant" clinically useful?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970029-9

7 January 2021

10.1016/S1470-2045(08)70029-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18237851%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

1 reference